Dedicated to Research Since 1993
  •  

    info@genesismarketinsights.com

Diabetes Drugs Market By Products & Services (Insulin Derivatives, Rapid-acting insulin, Intermediate-acting insulin, Long-acting insulin) By Application (Type 1 Diabetes, Type 2 Diabetes) - Global outlook Analysis and Industry Forecast, 2017-2022.

 Healthcare and Pharmaceuticals

Report Overview

GLOBAL DIABETES DRUG MARKET was valued at USD 47.2 Billion in the year 2017. Global Diabetes Drug Market is further estimated to grow at a CAGR of 7.09% from 2018 to reach USD 70.9 Billion by the year 2023. North America region holds the highest market share in 2017 and Asia-Pacific is considered as the fastest growing market in the forecasted period. At a country level, developed markets the U.S. holds a substantial market share in 2017 and it is projected to grow at a gradual pace in the coming years.

Abbott Laboratories (U.S.), Novartis AG (Switzerland), Novo Nordisk (Denmark), Bayer Healthcare AG (Germany) , Johnson & Johnson (U.S) and Sanofi (France) are some of the key players in the Diabetes Drug Market with Novo Nordisk (Denmark) holding the significant market share because of its better global presence both at production and at an operational level. Rising research and development expenses to address the changing demand of end users. Similarly, growth strategies such as acquisition, merger, and expansion of the distribution network were few techniques adopted by most of the top players in the last 5 years.

Drivers:

            Improved diagnosis and advances in treatment

            Increasing diabetic population

Restraints:

            Lack of awareness among people

            Increased Risk of Cardiovascular Complications

Opportunities:

            Launching of advance and new Anti-Diabetes Drugs

            High growth opportunity in the Emerging Market

Challenges:

            Other emerging therapy markets

            Patent Expiries and Rising Competition of Generic Drugs

The global diabetes drug market id segmented on the basis of products & services, by application and by region. On the basis of products and services, the Insulin Derivative segment is expected to hold the highest market share during the forecast period. Due to its high price, rising geriatric population and need & demand for insulin.

On the basis of application, the market is segmented as type 1 and type 2 diabetes, in which type 2 diabetes holds the highest market share owing to the 90% of diabetic patients suffering from type 2 diabetes.

Key Benefits for Stakeholders

Diabetes Drug Manufacturers and biotechnological institute

Blood banks, private hospitals and institutes

Research and Consulting organization.

Medical research laboratories

By Products & Services

Insulin Derivatives

            Rapid-acting insulin

            Intermediate-acting insulin

            Long-acting insulin

Oral Diabetic Medication Drugs

            Sulfonylurea

            Metformin

            Alpha-Glucosidase inhibitor

            Thiazolidinediones

            Biguanide

            Meglitinides

            GPP4-Inhibitors

            GLP-1

By Application

Type 1 Diabetes

Type 2 Diabetes

By Region

North America

Europe

Asia-Pacific

RoW

Key Market Players

Abbott Laboratories       

AstraZeneca PLC           

Bayer Healthcare AG     

Dexcom Inc.     

GlaxoSmithKline PLC     

Johnson & Johnson        

Sanofi  

Merck & Co.      

Novartis AG      

Novo Nordisk

(Another brief information of 10 companies will be provided in the report.)

Research Methodology:

Genesis Market Insights follows in-depth Research Methodology focused on reducing deviation in the collected data. GMI offers the most precise evaluations and projection for the market numbers. GMI engages following Market Engineering techniques –

  1. Raw Market Data is collected and compared with the Existing in-house Data on a broad front.
  2. Both Bottom-Up and Top-Down approaches are analyzed for segmenting and estimating measurable aspects of the market.
  3. To avoid bias, we filter the collected data collected from authenticated sources.
  4. GMI has a well proven Statistical Modeling System for estimates and forecasts.
  5. Further, the report findings are validated with the Industry Expert Panel on face to face or telephonic interviews.
  6. Panelists are approached from Leading Enterprises across the value chain including manufacturers, suppliers, technology providers, domain experts and buyers so as to validate a thorough and balanced market overview.

Detailed customization is also available for you. Further, if the report listed above does not meet with your key requirements. Our customized research report will analytically cover the required market information you need which will help you to plan your business decisions.

Table Of Content

1. Introduction

1.1 Market Vision

       1.1.1 Market Definition

       1.1.2 Market Scope

1.2 Limitations

1.3 Stakeholders

2. Research Methodology

2.1. Research Process

       2.1.1. Secondary Research

             2.1.1.1. Key Data from Secondary Research

       2.1.2. Primary Research

             2.1.2.1. Key Data from Primary Research

             2.1.2.2. Breakdowns of Primary Interviews

2.2. Market Size Estimation

       2.2.1. Bottoms-Up Approach

       2.2.2. Top-Down Approach

       2.2.3. Annual Revenue Process

2.3. Data Triangulation 

2.4. Research Assumptions 

       2.4.1. Assumption

3. Executive Summary

4. Market Overview

4.1. Introduction

4.2. Drivers

4.3. Restraints

4.4. Opportunities

4.5. Challenges

4.6. Regulations

4.7. Supply Chain/Value Chain Analysis

4.8. Patent & Standards

5. Industry Trends

5.1. Introduction

5.2. Porter’s Five Forces Analysis

       5.2.1. Threat of New Entrants

       5.2.2. Threat of Substitutes

       5.2.3. Bargaining Power of Buyers

       5.2.4. Bargaining Power of Suppliers

       5.2.5. Intensity of Competitive Rivalry

6. Diabetes Drug Market, By Products & Services

6.1. Insulin Derivatives

            6.1.1 Rapid-acting insulin

            6.1.2 Intermediate-acting insulin

            6.1.3 Long-acting insulin

6.2. Oral Diabetic Medication Drugs

6.2.1 Sulfonylurea

6.2.2 Metformin

6.2.3 Alpha-Glucosidase inhibitor

6.2.4 Thiazolidinediones

6.2.5 Biguanide

6.2.6 Meglitinides

6.2.7 GPP4-Inhibitors

6.3 GLP-1

7. Diabetes Drug Market, By Application

7.1. Type 1 Diabetes

7.2. Type 2 Diabetes

8. Geographical Analysis

8.1. Introduction

8.2. North America

       8.2.1. U.S.

       8.2.2. Canada

       8.2.3. Mexico

8.3. Europe

       8.3.1. U.K.

       8.3.2. Germany

       8.3.3. Italy

       8.3.4. France

       8.3.5. RoE

8.4. Asia Pacific

       8.4.1. South Korea

       8.4.2. China

       8.4.3. Japan

       8.4.4. South Korea

       8.4.5. RoAPAC

8.5. RoW

       8.5.1. Latin America

       8.5.2. Middle East and Africa

9. Company Profiles

(Business Overview, Financial Overview, Product write Up, Recent Developments)

9.1. Abbott Laboratories 

9.2 AstraZeneca PLC     

9.3 Bayer Healthcare AG

9.4 Dexcom Inc.

9.5 GlaxoSmithKline PLC

9.6 Johnson & Johnson   

9.7 Sanofi         

9.8 Merck & Co.

9.9 Novartis AG 

9.10 Novo Nordisk 

(Another brief information of 10 companies will be provided in the report.)

10. Competitive Analysis

10.1. Introduction

10.2. Market Positioning of Key Players

10.3 Competitive Strategies Adopted by Leading Players

        10.3.1. Investments & Expansions

        10.3.2. New Product Launches

        10.3.3. Mergers & Acquisitions

        10.3.4. Agreements, Joint Ventures, and Partnerships

11. Appendix

11.1. Questionnaire

11.2. Available Customizations 

11.3. Upcoming Events (Trade Fair, Exhibitions, Conferences)

 

List of Tables (23 Tables)

 

Table 1: Diabetes Drugs Market, Global, Approved Indications for Lantus, 2017

Table 2: Diabetes Drugs Market, Global, Approved Indications for Levemir, 2017

Table 3: Diabetes Drugs Market, Global, Approved Indications for Tresiba, 2017

Table 4: Diabetes Drugs Market, Global, Approved Indications for Toujeo, 2017

Table 5: Diabetes Drugs Market, Global, Approved Indications for Humalog, 2017

Table 6: Diabetes Drugs Market, Global, Approved Indications for Novolog, 2017

Table 7: Diabetes Drugs Market, Global, Approved Indications for Apidra, 2017

Table 8: Diabetes Drugs Market, Global, Approved Indications for Victoza, 2017

Table 9: Diabetes Drugs Market, Global, Approved Indications for Trulicity, 2017

Table 10: Diabetes Drugs Market, Global, Approved Indications for Januvia, 2017

Table 11: Diabetes Drugs Market, Global, Approved Indications for Galvus, 2017

Table 12: Diabetes Drugs Market, Global, Approved Indications for Tradjenta, 2017

Table 13: Diabetes Drugs Market, Global, Approved Indications for Invokana, 2017

Table 14: Diabetes Drugs Market, Global, Approved Indications for Jardiance, 2017

Table 15: Diabetes Drugs Market, Global, Approved Indications for Farxiga, 2017

Table 16: Diabetes Drugs Market, Global, Approved Indications for Soliqua, 2017

Table 17: Diabetes Drugs Market, Global, Approved Indications for Xultophy, 2017

Table 18: Diabetes Drugs Market, Global, Approved Indications for Janumet, 2017

Table 19: Market, Global, Approved Indications for Qtern, 2017

Table 20: Diabetes Drugs Market, Global Annual Revenue Forecast for Key Products ($m), 2018–2023)

Table 21: Diabetes Drugs Market, Global, Generic Usage across Key Indications, 2017

Table 22: Diabetes Drugs Market, Global Annual Revenue within Diabetes by Company, 2018–2023

Table 23: Abbreviations

 

List of Figures (79 Figures)

 

Figure 1: Diabetes Drugs Market, Global, Epidemiology Patterns for T1DM, 2018–2023

Figure 2: Diabetes Drugs Market, Global, Epidemiology Patterns for T2DM, 2018–2023

Figure 3: Diabetes Drugs Market, Global, Market Share Projections for Key Established Products, 2018–2023

Figure 4: Diabetes Drugs Market, Global, Market Share Projections for Key Upcoming Products, 2018–2023

Figure 5: Diabetes Drugs Market, Global, Percentage Change in Market Share for Key Products 2018–2023

Figure 6: Diabetes Drugs Market, Global, Key Marketed Products and Approved Indications, 2017

Figure 7: Diabetes Drugs Market, Global Annual Revenue for Lantus ($bn), 2017–2023

Figure 8: Diabetes Drugs Market, Global Annual Revenue for Levemir ($bn), 2017–2023

Figure 9: Diabetes Drugs Market, Global Annual Revenue for Tresiba ($bn), 2018–2023

Figure 10: Diabetes Drugs Market, Global Annual Revenue for Toujeo ($bn), 2015–2023

Figure 11: Diabetes Drugs Market, Global Annual Revenue for Humalog ($bn), 2017–2023

Figure 12: Diabetes Drugs Market, Global Annual Revenue for Novolog ($bn), 2017–2023

Figure 13: Diabetes Drugs Market, Global Annual Revenues for Apidra ($m), 2009–2023

Figure 14: Diabetes Drugs Market, Global Annual Revenues for Victoza ($bn), 2009–2023

Figure 15: Diabetes Drugs Market, Global Annual Revenue for Trulicity ($bn), 2014–2023

Figure 16: Diabetes Drugs Market, Global Annual Revenue for Januvia ($bn), 2017–2023

Figure 17: Diabetes Drugs Market, Global Annual Revenue for Galvus ($bn), 2007–2023

Figure 18: Diabetes Drugs Market, Global, And Annual Revenues for Tradjenta ($m), 2011–2023

Figure 19: Diabetes Drugs Market, Global Annual Revenues for Invokana ($bn), 2013–2023

Figure 20: Diabetes Drugs Market, Global Annual Revenue for Jardiance ($bn), 2014–2023

Figure 21: Diabetes Drugs Market, Global Annual Revenue for Farxiga ($bn), 2013–2023

Figure 22: Diabetes Drugs Market, Global Annual Revenues for Soliqua 100/33 ($m), 2017–2023

Figure 23: Diabetes Drugs Market, Global Annual Revenue for Xultophy ($bn), 2017–2023

Figure 24: Diabetes Drugs Market, Global Annual Revenue for Janumet ($bn), 2007–2023

Figure 25: Diabetes Drugs Market, Global Annual Revenue for Qtern ($m), 2017–2023

Figure 26: Diabetes Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017

Figure 27: Diabetes Drugs Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2017

Figure 28: Diabetes Drugs Market, Global, T1DM and T2DM Pipeline by Stage of Development, 2017

Figure 29: Diabetes Drugs Market, Global, T1DM and T2DM Pipeline by Molecule Type, 2017

Figure 30: Diabetes Drugs Market, Global, Pipeline by Molecular Target, 2017

Figure 31: Diabetes Drugs Market, Global, T1DM and T2DM Pipeline by Molecular Target, 2017

Figure 32: Diabetes Drugs Market, Clinical Trial Failure Rates by Stage of Development and Overall Clinical Trial Attrition Rate (%), 2006–2017

Figure 33: Diabetes Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Indication (%), 2006–2017

Figure 34: Diabetes Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rate by Molecule Type (%), 2006–2017

Figure 35: Diabetes Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rate by Molecular Target (%), 2006–2017

Figure 36: Diabetes Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2017

Figure 37: Diabetes Drugs Market, Global, Clinical Trial Duration by Indication and Stage of Development (months), 2006–2017

Figure 38: Diabetes Drugs Market, Global, Clinical Trial Duration by Molecule Type and Stage of Development (months), 2006–2017

Figure 39: Diabetes Drugs Market, Global, Clinical Trial Duration by Molecular Target and Stage of Development (months), 2006–2017

Figure 40: Diabetes Drugs Market, Global, Clinical Trial Size by Stage of Development, 2006–2017

Figure 41: Diabetes Drugs Market, Global, Clinical Trial Size by Indication and Stage of Development (participants), 2006–2017

Figure 42: Diabetes Drugs Market, Global, Clinical Trial Size by Molecule Type and Stage of Development (participants), 2006–2017

Figure 43: Diabetes Drugs Market, Global, Clinical Trial Size by Molecular Target and Stage of Development (Participants), 2006–2017

Figure 44: Diabetes Drugs Market, Global, Aggregate Clinical Program Size by Stage of Development, 2006–2017

Figure 45: Diabetes Drugs Market, Global, Aggregate Clinical Program Size by Indication and Stage of Development (participants), 2006–2017

Figure 46: Diabetes Drugs Market, Global, Aggregate Clinical Program Size by Molecule Type and Stage of Development (participants), 2006–2017

Figure 47: Diabetes Drugs Market, Global, Aggregate Clinical Program Size by Molecular Target and Stage of Development (participants), 2006–2017

Figure 48: Diabetes Drugs Market, Global, Revenue Forecast for Semaglutide (NN-9535) ($bn), 2017–2023

Figure 49: Diabetes Drugs Market, Global, Revenue Forecast for Oral Semaglutide (OG-217SC) ($bn), 2020–2023

Figure 50: Diabetes Drugs Market, Global, Revenue Forecast for ITCA 650 ($bn), 2018–2023

Figure 51: Diabetes Drugs Market, Global, Revenue Forecast for Sotagliflozin ($bn), 2018–2023

Figure 52: Diabetes Drugs Market, Global, Revenue Forecast for Ertugliflozin ($m), 2017–2023

Figure 53: Diabetes Drugs Market, Global Annual Revenue Forecast, 2018–2023

Figure 54: Diabetes Drugs Market, Global Annual Revenue Forecast for Premium and Generic Products ($bn), 2018–2023

Figure 55: Diabetes Drugs Market, Global Annual Revenue Forecast for Insulin Receptors ($bn), 2018–2023

Figure 56: Diabetes Drugs Market, Global Annual Revenue Forecast for GLP-1 Receptors, 2018–2023

Figure 57: Diabetes Drugs Market, Global Annual Revenue Forecast for SGLT-2 Inhibitors, 2018–2023

Figure 58: Diabetes Drugs Market, Global Annual Revenue Forecast for DPP-4 Inhibitors, 2018–2023

Figure 59: Diabetes Drugs Market, Global, Cluster by Growth and Market Share, 2018–2023

Figure 60: Diabetes Drugs Market, Global, Forecast Market Share by Company (%), 2018–2023

Figure 61: Diabetes Drugs Market Global, Companies by Compound Annual Growth Rate (%), 2018–2023

Figure 62: Diabetes Drugs Market, Global, Revenue by Route of Acquisition, 2018–2023

Figure 63: Diabetes Drugs Market, Global, Novo Nordisk and Annual Revenue Forecast, ($bn), 2018–2023

Figure 64: Diabetes Drugs Market, Global, Eli Lilly and Annual Revenue Forecast ($bn), 2018–2023

Figure 65: Diabetes Drugs Market, Global, Sanofi and Annual Revenue Forecast ($bn), 2018–2023

Figure 66: Diabetes Drugs Market, Global, AstraZeneca and Annual Revenue Forecast ($bn), 2018–2023

Figure 67: Diabetes Drugs Market, Global, Johnson & Johnson and Annual Revenue Forecast ($bn), 2018–2023

Figure 68: Diabetes Drugs Market, Global, Merck and Co and Annual Revenue Forecast ($bn), 2018–2023

Figure 69: Diabetes Drugs Market, Global, High-activity and Late-stage Pipeline Developers by Company Type, 2018–2023

Figure 70: Diabetes Drugs Market, Global, Pipeline Developers by Level of Diabetes Specialization, 2018–2023

Figure 71: Diabetes Drugs Market, Global, Proportion of Total Company Revenue Attributable to Diabetes, 2018–2023

Figure 72: Diabetes Drugs Market, Licensing Deals by Region, Value and Year, 2006–2017

Figure 73: Diabetes Drugs Market, Global, Number of Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006–2017

Figure 74: Diabetes Drugs Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006–2017

Figure 75: Diabetes Drugs Market, Global, Licensing Deals Valued at $100m and above, 2006–2017

Figure 76: Diabetes Drugs Market, Global, Co-development Deals Valued at $100m and above, 2006–2017

Figure 77: Diabetes Drugs Market, Global, Co-development Deals by Region, Value and Year, 2006–2017

Figure 78: Diabetes Drugs Market, Global, Number of Co-development Deals by Value and Stage of Development, 2006–2017

Figure 79: Diabetes Drugs Market, Global, Co-development Deals by Molecule Type and Molecular Target, 2006–2017

 

Summary

No Content Available.

PURCHASE OPTIONS

ASK FOR SPECIAL PRICING

Related Reports